coronavirus-specific t cell (cst)
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 2, 2021 (NCT05447013)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05141058 | Phase 1 | Oct 19, 2021 | Georgetown University |
| NCT05447013 | Phase 1/Phase 2 (Phase 2) | Jun 2, 2021 | Aristotle University of Thessaloniki, George Papanicolaou Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aristotle University of Thessaloniki | Academic/Hospital | 1 | 0 | 1 | 2021 |
| George Papanicolaou Hospital | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1